X-Linked Dystonia Parkinsonism Clinical Trial
Official title:
MINGO Supplemental Trial in X-linked Dystonia Parkinsonism Patients: A Prospective Randomized, Open-labeled, Parallel Group Trial
To see whether MINGO, a food supplement, will be able to lessen the drastic weight loss seen among X-linked Dystonia Parkinsonism patients.
X-linked dystonia parkinsonism (XDP, formerly known as DYT3) occurs primarily in Filipino
males and is characterized by neurodegenerative dystonia and parkinsonism. It is currently
recognized to have wide phenotypic variability relating to age of onset, location of disease
onset and rate of severity/disease progression. Most patients begin with focal dystonia that
generalizes with the development of parkinsonism later in disease course. XDP patients suffer
from severe nutritional loss due to symptoms such as dysphagia, loss of appetite, and
consistently high metabolic requirements brought about by their movement disorder.
Approximately 79% of patients with XDP have experienced rapid weight loss since the onset of
their disease. It is the aim of the researchers to assess the clinical usefulness of adding a
nutritional supplement to the daily dietary needs of these patients.
MINGO is a supplement consisting of local ingredients such as moringa, rice and mung beans,
which can be added to any type of edible paste, food, and liquid. Mingo has gained popularity
as an emergency food in disaster relief operations due to the ease of its preparation, its
high nutritional value and relatively low price. For the last two years, it has also been
used as an agent for nutritional build up in malnourished populations of children. This study
will provide valuable information on whether patients with XDP can increase their weight by
consuming MINGO, which will lead to improvements in the patients' medical care and wellbeing.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Available |
NCT05592028 -
High Intensity Focused Ultrasound for X-linked Dystonia-parkinsonism
|